Translating NSABP B-51 findings into practice: rethinking regional nodal irradiation in breast cancer

The recently published NSABP B-51/RTOG 1304 trial by Mamounas et al. (1) represents a landmark in the ongoing effort to de-escalate therapy in breast cancer. It is the only prospective, randomized trial to evaluate whether regional nodal irradiation (RNI) can be safely omitted in patients with initially node-positive breast cancer who achieve nodal pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). This multicenter phase III study enrolled 1,641 patients with cT1–3N1M0 breast cancer who were treated with NAC and followed for a median of nearly 5 years. Approximately 20% of the participants had T3 tumors, although those with cN2, cN3, or cT4 disease were excluded. Axillary status was confirmed by fine-needle aspiration or core biopsy, and post-NAC axillary surgery included either axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB), with or without ALND. Patients were stratified by axillary procedure, hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, breast pCR, and receipt of adjuvant chemotherapy. Those randomized to the radiotherapy (RT) arm received chest wall radiation therapy plus RNI after mastectomy or whole breast irradiation (WBI) with RNI after breast-conserving surgery (BCS), while those in the experimental arm received WBI alone after BCS or no radiation at all after mastectomy.

The primary endpoint of the trial was invasive breast cancer recurrence-free interval (IBCRFI), defined as local, regional, or distant recurrence, or breast cancer-specific death. Secondary endpoints included isolated locoregional recurrence-free interval (LRRFI), distant recurrence-free interval (DRFI), disease-free survival (DFS), overall survival (OS), and treatment-related toxicity. Between 2013 and 2020, 1,556 patients (772 in the RNI group and 784 in the no-RNI group) were evaluable. Forty percent of patients were aged ≤49 years, 20% had cT3 tumors, 21% had triple-negative breast cancer (TNBC), 56% were HER2-positive, 42% underwent mastectomy, 55% received SLNB, 22% did not achieve breast pCR, and only 1% received adjuvant chemotherapy. After a mean follow-up of 59.5 months, there was no significant difference in IBCRFI, with 5-year estimates of 92.7% in the RNI group versus 91.8% in the no-RNI group [hazard ratio (HR) 0.88; 95% confidence interval (CI): 0.60–1.29; P=0.51]. Subgroup analyses did not reveal variation by age, type of surgery, axillary approach, receptor status, HER2 status, or breast pCR.

However, biological subtype-specific patterns were observed. In patients with TNBC, outcomes were unexpectedly worse with RNI (HR 2.30; 95% CI: 1.00–5.25), while in HR-positive/HER2-negative disease there was a trend favoring RNI (HR 0.41; 95% CI: 0.17–0.99). These differences underscore the importance of considering subtype-specific effects when interpreting the findings. The B-51 trial was methodologically robust, employing stratified randomization across molecular subtypes, stringent radiation quality assurance, strong protocol adherence, and inclusion of both mastectomy and BCS patients, which enhance the generalizability and reliability of the results. Nonetheless, several limitations must be acknowledged. Only 109 IBCRFI events occurred, well below the 172 required for full statistical power, raising the possibility of a type II error. The trial’s time-driven design and relatively short follow-up restrict definitive conclusions, particularly in HR-positive/HER2-negative disease where late recurrences are common (2). Additionally, 20% of patients did not achieve breast pCR, yet disease volume was not detailed. Importantly, adjuvant therapies now considered standard of care for residual disease, including capecitabine (3), trastuzumab emtansine (T-DM1) (4), abemaciclib (5), and olaparib (6), were not widely available during the whole study period.

Biological mechanisms underlying subtype-specific responses

The divergent effects of RNI across breast cancer subtypes in B-51 warrant deeper mechanistic exploration, as they challenge the notion of RT as a universally beneficial adjuvant modality. The unexpected detriment observed with RNI in TNBC patients achieving ypN0 status may reflect fundamental differences in how radiation interacts with the tumor immune microenvironment across biological contexts.

TNBC is characterized by higher tumor mutational burden, increased tumor-infiltrating lymphocytes, and greater immunogenicity compared to other subtypes (7,8). Regional lymph nodes serve as critical immune compartments where antigen presentation, T-cell priming, and immune memory formation occur. Chen et al. demonstrated that immune-activated regional lymph nodes predict improved survival in early-stage TNBC, suggesting that preserving intact nodal immune architecture may be therapeutically advantageous (7). Irradiation of these lymph nodes, even at standard doses, may disrupt this delicate immune ecosystem by depleting circulating lymphocytes, impairing antigen trafficking, and reducing immune surveillance capacity—effects that could outweigh any local disease control benefit when microscopic disease burden is already eradicated by chemotherapy.

This hypothesis aligns with emerging radiobiology data showing that while focused RT can enhance antitumor immunity through immunogenic cell death and release of damage-associated molecular patterns, extensive nodal irradiation may have paradoxically immunosuppressive effects (9). In TNBC, where systemic immune control may be more critical than locoregional sterilization in ypN0 patients, this balance may tip against RNI. The integration of immune checkpoint inhibitors such as pembrolizumab into neoadjuvant regimens for TNBC further complicates this picture, as these agents fundamentally alter the immune landscape and may render traditional radiation fields counterproductive (10).

Conversely, the trend favoring RNI in HR-positive/HER2-negative disease likely reflects the distinct biology of luminal tumors. These cancers exhibit lower immunogenicity, slower proliferation kinetics, and greater propensity for late dormant micrometastatic reactivation (2). In this context, the mechanical cytoreductive effect of radiation may remain relevant even in the absence of pathologically detectable disease, as occult microscopic foci in regional nodes may persist despite systemic therapy. The indolent natural history of HR-positive disease means that late recurrences beyond 5 years are common, and the full benefit of RNI may only become apparent with extended follow-up exceeding a decade (2).

Integration with evolving paradigms of response-adapted therapy

The B-51 results must be contextualized within the broader evolution toward response-adapted, precision-guided de-escalation strategies in breast cancer. This trial contributes to an expanding evidence base suggesting that anatomic staging systems developed in the pre-NAC era inadequately capture modern risk stratification. Patients achieving ypN0 status represent a biologically selected cohort with chemosensitive disease, and their prognosis may diverge substantially from historical cohorts with similar anatomic presentations but without exposure to effective systemic therapy.

This paradigm parallels developments in other breast cancer management domains. The ACOSOG Z0011 trial demonstrated that ALND could be safely omitted in select patients with limited sentinel node involvement treated with BCS and systemic therapy, fundamentally altering surgical practice (11). Similarly, the AMAROS trial showed equivalence between ALND and axillary RT for sentinel node-positive disease, suggesting that RT could substitute for surgery in providing regional control (12). B-51 extends this de-escalation logic further, asking whether any axillary-directed therapy beyond SLNB is necessary in patients achieving complete nodal response to NAC.

However, critical differences distinguish B-51 from these earlier trials. Unlike Z0011, where residual disease was present but deemed clinically insignificant, B-51 addresses patients with no pathologic evidence of nodal disease post-treatment. This raises the question of whether achieving ypN0 represents true disease eradication or merely sampling error—particularly given that 55% of B-51 patients underwent SLNB alone, which carries an approximate 15% false-negative rate after NAC (13). Targeted axillary dissection (TAD), which combines SLNB with removal of clipped positive nodes, improves staging accuracy and reduces false-negative rates to below 5% (13). In the era of personalized decision-making regarding RNI omission, TAD may become the preferred axillary staging approach, providing greater confidence in true ypN0 status.

In the prospective RAPCHEM study, de Wild et al. demonstrated the safety of locoregional RT de-escalation in patients with cT1–2N1 breast cancer and ≤3 suspicious nodes on imaging. Among 838 participants, 681 underwent ALND. Patients with ypN0 disease received only whole-breast RT (after BCS) or no RT (after mastectomy), resulting in a 5-year locoregional recurrence (LRR) rate of 2.2%. For ypN1 patients, local RT without RNI yielded similarly low 5-year LRR rates (2.2%; 1% when guidelines were followed) (14). In contrast, a pooled analysis of three German trials reported a higher 5-year LRR of 15.2% in ypN0 patients undergoing mastectomy without RT versus 11.3 in patients treated with RT, likely reflecting inclusion of a greater proportion of high-risk (stage III) cases (15).

The B-51 findings also intersect with genomic risk stratification tools such as Oncotype DX and MammaPrint, which inform chemotherapy decisions but have not been validated for RT guidance. Future integration of molecular signatures reflecting residual disease burden, immune activation, and metastatic potential could refine patient selection for RNI omission beyond pathologic response alone. Radiogenomic approaches combining imaging biomarkers with genomic data may identify patients at highest risk for occult residual disease despite ypN0 pathology, warranting continued RNI consideration.

Clinical implications for multidisciplinary decision-making

Translating B-51 into everyday clinical practice requires nuanced, patient-centered discussions within multidisciplinary tumor boards. The trial provides reassurance that RNI omission is safe in aggregate for ypN0 patients, but individual risk assessment must incorporate multiple factors beyond pathologic nodal status.

For HER2-positive disease, where 56% of B-51 participants clustered and outcomes were favorable in both arms, RNI omission appears reasonable in ypN0 patients regardless of breast response or initial tumor burden. The high efficacy of modern HER2-directed therapies, including T-DM1 for residual disease and the emerging use of trastuzumab deruxtecan (T-DXd), provides robust systemic control that likely mitigates any marginal benefit from RNI (4,16). Clinicians should feel confident recommending RNI omission in this subset, focusing instead on optimizing systemic therapy sequencing.

In TNBC achieving ypN0, the B-51 data suggest RNI omission may actually be preferable to standard treatment. However, this recommendation must be tempered by recognition that the observed detriment with RNI was of borderline statistical significance and based on relatively few events. Clinicians should counsel patients that while RNI appears unnecessary and potentially counterproductive, this finding requires validation in independent cohorts. The ongoing incorporation of pembrolizumab into TNBC neoadjuvant regimens adds complexity, as immune checkpoint inhibition may further amplify the importance of preserving regional immune function. Until longer-term data mature and mechanistic studies clarify the interplay between RT and immunotherapy, shared decision-making should emphasize that evidence supports RNI omission in ypN0 TNBC, with careful surveillance for LRR.

For HR-positive/HER2-negative disease, clinical decision-making becomes most challenging. The numerical reduction in recurrence with RNI (4.5% vs. 9.8%) suggests potential benefit, but this trend did not reach statistical significance and may reflect early manifestation of a long-term advantage. In this subtype, clinicians must weigh competing considerations: the trial’s short follow-up relative to the disease’s natural history, the patient’s age and competing mortality risks, the presence of adverse features such as lymphovascular invasion or high tumor grade, and the completeness of axillary staging (SLNB vs. TAD vs. ALND). For young patients with high-grade tumors and SLNB-only staging, RNI may remain prudent despite ypN0 status. For older patients with favorable biology and TAD confirmation of ypN0, omission is reasonable. These decisions exemplify the shift toward personalized medicine, where rigid protocols give way to individualized risk-benefit assessments.

Importantly, B-51 does not address several clinically relevant scenarios. Patients with cT4 disease, cN2/3 involvement, or residual pathologic nodal disease (ypN+) were either excluded or represent populations where RNI clearly remains indicated. Additionally, the trial does not inform management of patients with ypN0 status who had extensive initial nodal burden (e.g., cN1 with multiple suspicious nodes on imaging), where occult residual disease risk may be higher despite negative pathology. In these gray zones, multidisciplinary teams must extrapolate cautiously, erring toward RNI when uncertainty is high.

Future directions: precision radiation oncology in the era of integrated biomarkers

The B-51 trial opens the door to a new chapter in radiation oncology, where treatment decisions are guided not by anatomic stage alone but by integrated assessment of tumor biology, treatment response, immune context, and molecular risk. Several key questions must be addressed to fully realize this vision.

First, we need prospective validation of biomarkers that predict which ypN0 patients harbor occult residual disease and would benefit from RNI. Circulating tumor DNA (ctDNA) has emerged as a powerful tool for detecting minimal residual disease in breast cancer, with studies demonstrating that ctDNA positivity after NAC strongly predicts recurrence (17). Incorporating ctDNA assessment into post-NAC management algorithms could identify a subset of pathologically node-negative patients who remain at high risk and merit RNI, while sparing truly disease-free patients’ unnecessary treatment. The I-SPY2 trial platform and similar adaptive designs offer frameworks for efficiently testing such biomarker-directed strategies.

Second, artificial intelligence and radiomics may enhance our ability to predict RNI benefit. Machine learning algorithms trained on pre- and post-treatment imaging, combined with clinical and pathologic data, could generate personalized risk scores that outperform traditional staging systems. Early studies suggest that radiomic features extracted from magnetic resonance imaging and positron emission tomography imaging can predict pCR to NAC and identify patients at high risk for distant recurrence (18). Extending these approaches to predict LRR risk in ypN0 patients could refine RNI decision-making.

Third, we must better understand the immunologic consequences of regional RT in the modern treatment landscape. As immune checkpoint inhibitors, antibody-drug conjugates, and other immunomodulatory agents become standard components of breast cancer therapy, the interaction between these drugs and radiation will grow increasingly important. Preclinical and translational studies should investigate optimal sequencing and field design to maximize synergy between RT and systemic immunotherapy. Spatially fractionated or intensity-modulated approaches that spare specific lymph node stations critical for immune priming may preserve antitumor immunity while providing disease control.

The Alliance A011202 trial will address whether radiation therapy alone to the undissected axilla and regional nodes is non-inferior to ALND plus RNI in patients with residual sentinel node disease after NAC (19). This study complements B-51 by examining patients with ypN+ disease and testing whether surgery can be replaced by RT in the post-NAC setting. Together, these trials will define the spectrum of axillary management options from complete de-escalation (no RNI in ypN0) to radiation-only approaches (RNI without ALND in ypN+), ultimately moving toward a response-adapted, surgery-sparing paradigm.

Finally, the 10-year follow-up of B-51 will be critical for definitively establishing the safety of RNI omission in HR-positive/HER2-negative disease. If the early trend favoring RNI in this subtype strengthens with longer follow-up, guidelines may need to stratify recommendations by both pathologic response and biological subtype. Conversely, if outcomes remain equivalent, this would provide strong evidence supporting universal RNI omission in ypN0 patients regardless of receptor status.

Conclusions

The NSABP B-51/RTOG 1304 trial fundamentally challenges longstanding assumptions about the necessity of RNI in breast cancer, demonstrating that RNI can be safely omitted in patients achieving ypN0 status after NAC. However, the trial’s true significance extends beyond this headline finding. The subtype-specific signals—potential detriment in TNBC, possible benefit in HR-positive disease—reveal that de-escalation is not a one-size-fits-all proposition but must be tailored to tumor biology and immune context.

In TNBC, preservation of regional immune function may supersede traditional radiation oncology goals of microscopic disease eradication, particularly when systemic immunotherapy is employed. In HR-positive/HER2-negative disease, the prolonged natural history demands patience and extended follow-up before definitively abandoning RNI. For HER2-positive patients, robust systemic therapy renders RNI largely unnecessary in the ypN0 setting.

As breast oncology advances toward precision medicine, the next frontier lies in integrating molecular response assessment, immune profiling, and advanced imaging to predict individual RNI benefit with greater accuracy than pathologic response alone. The convergence of ctDNA monitoring, radiogenomics, artificial intelligence, and immunotherapy will enable increasingly refined, biologically rational treatment decisions. In this emerging landscape, the B-51 trial will be remembered not merely for demonstrating that RNI can be omitted, but for catalyzing a fundamental reconceptualization of how we deploy RT in the molecularly defined, response-adapted era of breast cancer care.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article has undergone external peer review.

Peer Review File: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-1837/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-1837/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Mamounas EP, Bandos H, White JR, et al. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy. N Engl J Med 2025;392:2113-24. [Crossref] [PubMed]
2. Ito M, Amari M, Sato A, et al. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast. 2024;73:103604. [Crossref] [PubMed]
3. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017;376:2147-59. [Crossref] [PubMed]
4. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28. [Crossref] [PubMed]
5. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024;42:987-93. [Crossref] [PubMed]
6. Yamauchi H, Toi M, Takayama S, et al. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer 2023;30:596-605. [Crossref] [PubMed]
7. Chen YY, Ge JY, Ma D, et al. Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. Front Oncol 2020;10:570981. [Crossref] [PubMed]
8. Loi S, Drubay D, Adams S, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol 2019;37:559-69. [Crossref] [PubMed]
9. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-70. [Crossref] [PubMed]
10. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020;382:810-21. [Crossref] [PubMed]
11. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75. [Crossref] [PubMed]
12. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-10. [Crossref] [PubMed]
13. Varghese J, Patani N, Wazir U, et al. Wire-Free Targeted Axillary Dissection: A Pooled Analysis of 1300+ Cases Post-Neoadjuvant Systemic Therapy in Node-Positive Early Breast Cancer. Cancers (Basel) 2024;16:2172. [Crossref] [PubMed]
14. de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 2022;23:1201-10. [Crossref] [PubMed]
15. Krug D, Lederer B, Seither F, et al. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019;26:3892-901. [Crossref] [PubMed]
16. Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020;382:610-21. [Crossref] [PubMed]
17. Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res 2019;25:4255-63. [Crossref] [PubMed]
18. Braman NM, Etesami M, Prasanna P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 2017;19:57. [Crossref] [PubMed]
19. Alliance for Clinical Trials in Oncology. A011202: A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1–3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. Available online: https://clinicaltrials.gov/ct2/show/NCT01901094